NVCR News and Press, NovoCure Limited From 02/28/19

Quarterly net revenues of $69.7 million, representing 30 percent growth versus the fourth quarter 2017 and 8 percent growth versus the third quarter 2018 Full year 2018 net revenues of $248.1 million, representing annual growth of 40 percent compared to 2017 Three additional phase...

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a...

Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields. Tumor Treating Fields is a cancer therapy th...

Novocure (NASDAQ: NVCR) announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will ...

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and issued a price target of $51 on shares of NovoCure Limited’s (NASDAQ: NVCR) stock. NovoCure is an oncology company engaged in the development of an incomparable cancer treatment employing tumor treating fields. ...

NEW YORK, Oct. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HomeStreet, Inc. (NASDAQ:HMST), Cousins Properties Incorporated (NYSE:CUZ...

NovoCure Limited (NVCR) Q3 2018 Earnings Conference Call October 25, 2018 08:00 AM ET Executives Ashley Cordova - Senior Vice President, Finance and Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - Chief Financial Of...

Gainers:  TIS +20% . TBIO +17% . SNBR +17% . LJPC +17% . ATNI +16% . IMMY +15% . TWTR +15% . XLNX +15% . TRVG +14% . MORN +14% . More news on: Orchids Paper Products Company, Translate Bio, Sleep Number Corporation, Stocks on the move, , Top stock marke...

The following slide deck was published by NovoCure in conjunction with their 2018 Q3 earnings Read more ...

NovoCure ( NVCR ) Q3 results: Revenues: $64.8M (+29.3%); Net Loss: ($11.7M) (+1.7%); Loss Per Share: ($0.13) (unch). More news on: NovoCure, Healthcare stocks news, Earnings news and commentary, Read more ...